Arrowhead (ARWR) is down -8.9%, or -$1.49 to $15.28.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Cautious Hold Rating on Arrowhead Pharmaceuticals Amid Uncertainty in Sarepta Partnership
- Arrowhead Pharmaceuticals Advances Phase 3 Study of Zodasiran for Cholesterol Management
- Arrowhead Pharmaceuticals Advances Phase 3 Study on Plozasiran for Hypertriglyceridemia
- Arrowhead doses first patient in YOSEMITE trial
- Arrowhead completes enrollment in SHASTA-3, SHASTA-4 and MUIR-3